Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Anemia
Description
A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN. MeSH
Hierarchy View
Subtype Terms (9)
Anemia, Aplastic
84 drugs (49 approved, 35 experimental)
Anemia, Hemolytic
17 drugs (15 approved, 2 experimental)
Anemia, Hypochromic
1 experimental drug
Anemia, Refractory
61 drugs (35 approved, 26 experimental)
Red-Cell Aplasia, Pure
17 drugs (14 approved, 3 experimental)
Phase 3 Indicated Drugs (31)
Phase 2 Indicated Drugs (45)
Phase 1 Indicated Drugs (53)
Other Experimental Indicated Drugs (29)
Organization Involved with Phase 4 Indications (163)
Abdelwahed, Mai Mahmoud Mohamed, M.D.
Aristotle University of Thessaloniki
Auerbach Hematology and Oncology
Carol Davila University of Medicine and Pharmacy
Centre for Global Health Research, Ghana
Chinese Academy of Medical Sciences
Christian Medical College, Vellore, India
Federal University of Juiz de Fora
Fundación Canaria Rafael Clavijo para la Investigación Biomédica
Hospital Joan XXIII de Tarragona, Tarragona, Spain
HOSPITAL UNIVERSITARIO DE CRUCES
Huazhong University of Science and Technology
IHS Dialysis Centre, Sf Ioan Nou Clinical Hospital
Institut Hospital del Mar d'Investigacions Mèdiques
Instituto de Desarrollo e Investigaciones Pediátricas Prof. Dr. Fernando E. Viteri
Jiangxi Provincial People's Hospital
Jining NO.1 People 's Hospital
Kwame Nkrumah University of Science and Technology
Laboratoire Innotech International
Lithuanian University of Health Sciences
National Cancer Institute (NCI)
National Health and Medical Research Council, Australia
National Institute for Health Research, United Kingdom
Pediatric Specialists of Virginia
People's Liberation Army of China
Services Institute of Medical Sciences, Pakistan
Shandong University of Traditional Chinese Medicine
St Joseph University of Beirut
Sunshine Lake Pharma Co., Ltd.
The Baruch Padeh Medical Center, Poriya
Universidad Autonoma de Nuevo Leon
University of British Columbia
University of California, Los Angeles
University of California, San Francisco
University of Las Palmas de Gran Canaria
University of Medicine and Dentistry of New Jersey
University of Naples Frederico II
University of Picardie Jules Verne
University of Texas, Galveston
Washington University in St. Louis
Organization Involved with Phase 3 Indications (181)
Anandabawa Kidney Dialysis Center, Jamnagar
Apollo Hospitals, Chennai, India
Bill and Melinda Gates Foundation
Caritas Teaching Hospital, Bucharest
Case Western Reserve University
Children's National Medical Center
Clinical Trials and Surveys Corp
Department of State for Health and Social Welfare, The Gambia
Dialysezentrum Straubing, Germany
ECOG-ACRIN Cancer Research Group
Elisabeth-TweeSteden Ziekenhuis
European Group for Blood and Marrow Transplantation
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Federal University of Rio Grande do Sul
Gottfried Wilhelm Leibniz Universität Hannover
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (GETAID)
Gujarat Kidney Foundation, Ahmedabad
Hannover Clinical Trial Center GmbH
IKDRC, Civil Hospital, Ahmedabad
Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti
International Center for Diarrheal Disease Research
Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)
Kenya Medical Research Institute
Maryland Medical Research Institute
Maternity and Children Hospital, Makkah
Medical University of South Carolina
Muljibhai Patel Urological Hospital
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institutes of Health (NIH)
Norwegian University of Science and Technology
Papua New Guinea Institute of Medical Research
Peterborough and Stamford Hospitals NHS Foundation Trust
Rawalpindi Medical College, Pakistan
Shields, Shields and Associates
State University of New York, Buffalo
Steven & Alexandra Cohen Children's Medical Center, New York
Taipei Veteran General hospital
Tropical Medicine Research Institute
University College Hospital, Nigeria
University of Alabama, Birmingham
University of Texas at Houston
University of Western Australia
Organization Involved with Phase 2 Indications (131)
Association of Oncological Hematologists
Blood and Marrow Transplant Clinical Trials Network
Center for International Blood and Marrow Transplant Research
Children's Medical Center Dallas
City of Hope National Medical Center
Clinica Universidad de Navarra
Department of Health and Human Services
European Organisation for Research and Treatment of Cancer
Feinstein Institute for Medical Research
FerruMax Pharmaceuticals, Inc.
Groupe Francophone des Myelodysplasies
Guangdong Prevention and Treatment Center for Occupational Diseases
Health Forever Product Limited. Lagos, Nigeria
Hospital Infantil Universitario Niño Jesús, Madrid, Spain
James Graham Brown Cancer Center
Jiangsu Hansoh Pharmaceutical Co., Ltd.
King Faisal Specialist Hospital
La Jolla Institute for Allergy & Immunology
Los Angeles Biomedical Research Institute
Medical Research Council, The Gambia
Methodist Cancer Center, Houston, Texas
National Center for Research Resources (NCRR)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute on Aging (NIA)
National Nutrition Agency, The Gambia
North Central Cancer Treatment Group
North Shore University Hospital
Oregon Health and Science University
Pediatric Brain Tumor Consortium
Research and Education Foundation of Michael Reese
The American Society of Hematology
The Korean Society of Pediatric Hematology Oncology
The Second People's Hospital of GuangDong Province
Universidad Autonoma de Barcelona
Universidad Autonoma de Madrid
University of Colorado, Denver
University of Illinois at Chicago
Organization Involved with Phase 1 Indications (21)
Organization Involved with Other Experimental Indications (75)
Centers for Disease Control and Prevention (CDC)
Cheikh Anta Diop University, Senegal
Dow University of Health Sciences
Englewood Hospital and Medical Center
Goiania Municipal Health Department
Hospital Infantil Dr. Robert Reid Cabral
Icahn School of Medicine at Mount Sinai
Institut de Cancerologie de l'Ouest Paul Papin
Institut National d'Etude et d'Action pour le Developpement de l'Education, Senegal
Joint Clinical Research Centre, Kampala, Uganda
National Center for Complementary and Integrative Health (NCCIH)
Office of Dietary Supplements (ODS)
Postgraduate Institute of Medical Education and Research
Sao Jose do Rio Preto University
Shenzhen Geno-Immune Medical Institute
Swiss Federal Institute of Technology
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
